Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
about
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsPatient preferences in the treatment of diabetic retinopathy.Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trialEffectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetesβ-cell function preservation after 3.5 years of intensive diabetes therapyEffect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.Insulin use, prescription patterns, regimens and costs.-a narrative from a developing country.Facilitating healthy coping in patients with diabetes: a systematic review.A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus.Early insulinization to prevent diabetes progression.Knowledge of insulin use and its determinants among Nigerian insulin requiring diabetes patientsPioglitazone: beyond glucose control.The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetesChoice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals.Efficacy of structured education in patients with type 2 diabetes mellitus receiving insulin treatment.Barriers to achieving glycemic targets: who omits insulin and why?Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus.Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice.
P2860
Q26767164-11F7319C-390E-47B5-B952-2A0C2C65BCC2Q33928715-B5795690-D3AF-4E2F-91C2-51AD28ADAC70Q34242531-F6D61AC1-4A3E-4547-8081-C07CF4CE6A49Q34374321-A643342F-F2CB-4BF3-A2D9-A0C6079BAF15Q34507074-37FC093D-5243-4C23-AAC7-78933E08787CQ34586302-C54A9534-1378-4278-9654-D85F19220A4EQ34783357-086605DF-0A4C-4726-BF03-2BD53D18FF8DQ36047178-2584F9FB-D54C-4A8A-9F12-0C08AEC5377BQ36252697-3C2A1529-9F71-4E5C-B495-E8651C74618FQ36513336-ADB24AD8-1AA9-4F0A-97B9-C65F2A0DBB79Q36545261-1E123F9B-D5F7-4646-81E4-DE7BC6F25308Q36971385-B9AC68E6-3F1C-4242-9B8B-7F4346BBC325Q37577178-5512BF37-6ECD-4F08-BD39-1FE3A4502215Q37601770-63032F19-E916-4704-963F-840199D73199Q37776510-1602C5E2-4408-44B3-897C-6B2C612A8FACQ37915625-DFC15440-9675-4030-8400-5980DE2D858BQ38095652-A4FB9221-2D14-4B83-9DB1-E2E4465861BBQ38115799-6983D732-16DF-4425-B5EE-D62E67691C39Q38129446-2C533E6A-396C-4C83-BB98-7EC077433003Q38246691-7309CEB2-5715-4A78-94B9-F2BE0BC4638BQ42171251-FB1A3F4D-1577-4E6D-8E34-8CED7DC9B32AQ42630239-0421FB13-13F2-4371-81A6-F3A176F4B434Q42933616-789B079F-73AB-40E6-AEE1-47DA83BE40B8Q44264038-BF0A7DF2-946A-4D1F-A435-0B302567D3E8Q45056742-C59FD5BD-4D63-4E53-B0F5-D2C3190F02B2Q48086602-A627FF4A-E6BA-4331-B3B7-B4FD20E396FEQ48287418-0F0A55F8-19C9-4853-B000-348473285658Q49742224-61F766A2-9626-4B3A-AE4F-AC9A176A0252Q51185982-A4173548-D90F-4735-9ED3-8383545AEE4FQ55288083-8DC0C686-149D-418D-AD53-573CFC5C545A
P2860
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@en
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@nl
type
label
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@en
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@nl
prefLabel
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@en
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@nl
P2093
P2860
P356
P1433
P1476
Insulin-based versus triple or ...... e 2 diabetes: which is better?
@en
P2093
Beverley Adams-Huet
Ildiko Lingvay
Jaime L Legendre
Philip Raskin
Polina F Kaloyanova
Song Zhang
P2860
P304
P356
10.2337/DC09-0653
P407
P577
2009-07-10T00:00:00Z